Clinical Trials

1,210 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05239741 2026-04-17

MK-3475-C66

100 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT05633602 2026-04-17

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

838 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06312137 2026-04-17

TroFuse-019

780 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06452277 2026-04-17

SOHO-02

444 enrolled

Advanced Non-small Cell Lung Cancer

NCT06589804 2026-04-17

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

158 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT06952504 2026-04-17

TroFuse-033

1,123 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT06966700 2026-04-17

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

2,400 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07061977 2026-04-17

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

336 enrolled

Locally Advanced Cervical Adenocarcinoma

NCT07216703 2026-04-17

TroFuse-036

1,023 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT07218380 2026-04-17

FORAGER-2

450 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT05317858 2026-04-16

LIMITLESS

30 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03520686 2026-04-15

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

Phase 3 Terminated

102 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04924062 2026-04-15

KEYNOTE-966

Phase 3 Completed

158 enrolled 19 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06096844 2026-04-15

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

304 enrolled

Lung Neoplasms

NCT06151574 2026-04-15

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

416 enrolled

Lung Neoplasms

NCT06524544 2026-04-15

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

320 enrolled

Carcinoma, Transitional Cell

NCT07361510 2026-04-15

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

750 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06422806 2026-04-14

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

365 enrolled

Sarcoma

Liposarcoma, Histiocytoma, Malignant Fibrous

NCT06623422 2026-04-14

INTerpath-009

680 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02506153 2026-04-13

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

1,301 enrolled 16 charts

Dermatologic

Melanoma

NCT02954874 2026-04-13

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

1,155 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03244384 2026-04-13

AMBASSADOR

739 enrolled

Ureteral Neoplasms

NCT03390504 2026-04-13

THOR

629 enrolled 32 charts 1 FDA

Urothelial Cancer

NCT03486873 2026-04-13

MK-3475-587

Other hematologic neoplasm

3,500 enrolled

Hematologic Neoplasms

NCT03914612 2026-04-13

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

813 enrolled 16 charts 2 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT04214067 2026-04-13

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

164 enrolled

Sarcoma

Carcinosarcoma

NCT06077760 2026-04-13

INTerpath-002

868 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06170788 2026-04-13

TroFuse-007

614 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06345729 2026-04-13

KANDLELIT-004

600 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06393374 2026-04-13

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

1,530 enrolled

Triple Negative Breast Neoplasms

NCT06743126 2026-04-13

SUPRAME

360 enrolled

Dermatologic

Melanoma, Cutaneous Malignant

NCT06793215 2026-04-13

Krascendo 2

600 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06841354 2026-04-13

TroFuse-011

1,000 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT07190248 2026-04-13

KANDLELIT-007

675 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07198074 2026-04-13

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

255 enrolled

Endometrial Neoplasms

NCT07276399 2026-04-13

OrigAMI-5

500 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07431827 2026-04-13

KANDLELIT-013

400 enrolled

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07524257 2026-04-13

ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC

494 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06764875 2026-04-09

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

840 enrolled

Gastrointestinal

HER2-positive Gastric Cancer

NCT06635824 2026-04-08

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

191 enrolled

Lung Neoplasms

NCT06989112 2026-04-08

DE-01

600 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Neoplasms, Endometrial Neoplasms

NCT07195695 2026-04-08

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07222566 2026-04-08

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

1,410 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT04657991 2026-04-07

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

257 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT05812807 2026-04-07

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

1,295 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT05911295 2026-04-07

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

412 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06632327 2026-04-07

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

1,100 enrolled

Lung Neoplasms

NCT06661720 2026-04-07

STRIKE

1,040 enrolled

Carcinoma, Renal Cell

NCT06758401 2026-04-07

Be6A Lung-02

714 enrolled